• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

    8/13/25 9:15:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CVM alert in real time by email
    • Memorandum of Understanding (MOU) signed with a leading Saudi Arabian pharma company which submitted the Breakthrough Medicine Designation to the Saudi Food and Drug Authority (SFDA)
    • Increasing interest in CEL-SCI from Saudi investment funds as Multikine advances through regulatory and drug distribution channels

    CEL-SCI Corporation (NYSE:CVM) today announced that a Breakthrough Medicine Designation application has been filed with the Saudi Food and Drug Authority (SFDA) for Multikine* (Leukocyte Interleukin, Injection) in the Kingdom of Saudi Arabia by one of the Kingdom's premier pharmaceutical and healthcare companies. CEL-SCI has signed a Memorandum of Understanding (MOU) with this Saudi pharma company for the commercialization of Multikine in Saudi Arabia. A final partnership agreement is expected during the 3rd quarter of 2025.

    Multikine is a cancer immunotherapy administered before surgery as a treatment for newly diagnosed previously untreated head and neck cancer. Its goal is to activate a person's immune system to fight cancer before the ravages of surgery, radiation and chemotherapy have weakened the immune system. In the world's largest head and neck cancer Phase 3 study, Multikine increased the 5-year survival rate of the target patient population to 73% vs 45% in patients treated with standard of care alone and halved the risk of death from 55% to 27%.

    According to the SFDA, the response time to a Breakthrough Medicine Designation application is approximately 60 days. Following the granting of Breakthrough Medicine Designation, Multikine would immediately become available for patient access and reimbursement/sale in Saudi Arabia.

    The Saudi pharma company is well positioned to procure reimbursement and to accelerate Multikine's sale and commercial launch.

    Several leading Saudi funds have expressed interest in investing in Multikine, CEL-SCI, and a potential joint venture to serve the wider Middle East and North Africa (MENA) market. CEL-SCI is working closely with First Berlin of Germany and its Saudi representatives to advance its commercialization program for Multikine.

    Martin Bailey, Managing Director and Founder of First Berlin, the lead advisor, commented, "CEL-SCI's prospective new partner is a prominent and innovative leader that has rendered many valuable healthcare services to the Kingdom. The Saudi pharma company's keen interest in Multikine to make patients' first cancer treatment more curative is very much in line with their forward-thinking approach and fits well with Saudi Arabia's Vision 2030 and the National Biotechnology Strategy. We look forward to facilitating the signing of a final partnership agreement and making Multikine available to patients as quickly as possible."

    "This MOU and the filing for Breakthrough Medicine Designation mark a significant advancement for Multikine's global regulatory, patient access/sale and commercial roll out," stated CEL-SCI CEO, Geert Kersten. "We've had a highly productive working relationship with this prestigious Saudi pharma company, First Berlin, and the SFDA and hope to see Multikine improve longevity and well-being for head and neck cancer patients in Saudi Arabia."

    About the SFDA's Breakthrough Medicine Program

    The SFDA Breakthrough Medicine Program aims to facilitate and accelerate development and review of new drugs that address unmet medical needs in the treatment of serious or life-threatening conditions in alignment with Saudi Arabia's Vision 2030 initiative. The program is voluntary and based on early dialogue with drug developers to optimize development plans and speed up evaluation. The goal is to ensure that promising medicines are available as soon as it can be concluded that the medicines' benefits justify their risks.

    Eligibility includes having to fulfill all of the following four criteria in order to gain a Breakthrough Medicine Designation:

    • Target serious debilitating or life-threatening conditions with unmet medical need.
    • The medicinal product is likely to offer major advantages over methods currently used.
    • The potential adverse effects of the medicinal product are considered to be outweighed by the benefits, allowing for the reasonable expectation of a positive benefit/risk balance.
    • The product is not registered at any regulatory authority at the time of submission of the designation request.

    About CEL-SCI Corporation

    CEL-SCI believes that boosting a patient's immune system before surgery, radiotherapy and chemotherapy have damaged it, should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.

    Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.

    The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital, inability to finalize a partnering agreement and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2024. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

    * Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250813431066/en/

    COMPANY CONTACT:

    Gavin de Windt

    CEL-SCI Corporation

    (703) 506-9460

     

    Get the next $CVM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Watson Robert Eugene bought $19,995 worth of shares (2,919 units at $6.85), increasing direct ownership by 359% to 3,733 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    7/29/25 7:56:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Kersten Geert R bought $199,999 worth of shares (29,197 units at $6.85), increasing direct ownership by 67% to 72,835 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    7/28/25 9:36:31 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Watson Robert Eugene bought $27,800 worth of shares (20,000 units at $1.39), increasing direct ownership by 451% to 24,431 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    5/10/24 9:04:18 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    Leadership Updates

    Live Leadership Updates

    View All

    CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

    CEL-SCI Corporation (NYSE:CVM) today reported financial results for the quarter ended June 30, 2024, as well as key recent clinical and corporate developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815767286/en/The table includes detailed results from the bias analysis. (Graphic: Business Wire) Clinical and Corporate Developments include: In July 2024, following the end of the third fiscal quarter, CEL-SCI reported the results of a bias analysis. The bias analysis, a standard process to ensure a trial's findings are reliable, was conducted in preparation for CEL-SCI's upcoming confirmatory Registration Study. This

    8/15/24 8:00:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEL-SCI Appoints Robert Watson as Chairperson of the Board

    CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to drive an efficient capital structure. During his career as CEO or President of private and publicly traded companies in the healthcare sector, Bob negotiated over a half dozen exits and more than $750 million in capital transactions including IPOs, secondary offerings, and debt in

    7/8/24 9:15:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEL-SCI Appoints Mario Gobbo to Its Board of Directors

    CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as investment banking and strategic advisory services. He has served as an officer or director for a number of companies including several biotech companies: Xcovery, Ocimum/Genelogic and Helix BioPharma. Prior to that, Mr. Gobbo worked in the financial industry for Lazard LLC, Swiss Bank Corporation, the European Bank for Reconstruction and Development, Natixis Bleichroeder, Inc., and International Finance Corporation

    4/23/24 9:00:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

    SC 13G/A - CEL SCI CORP (0000725363) (Subject)

    2/8/23 10:48:28 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

    SC 13G/A - CEL SCI CORP (0000725363) (Subject)

    4/11/22 1:55:14 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

    SC 13G/A - CEL SCI CORP (0000725363) (Subject)

    2/11/22 7:53:04 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Watson Robert Eugene

    4 - CEL SCI CORP (0000725363) (Issuer)

    7/29/25 5:20:52 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Baillavoine Bruno Jean-Marie

    4 - CEL SCI CORP (0000725363) (Issuer)

    7/29/25 5:15:08 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Senior Vice President Cipriano John

    4 - CEL SCI CORP (0000725363) (Issuer)

    7/29/25 5:12:13 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

    CEL-SCI to sign partnership agreement in Saudi Arabia—Potential for patient access and reimbursement/sale of Multikine in Saudi Arabia within approximately 60 days following filing for Breakthrough Medicine Designation CEL-SCI Corporation (NYSE:CVM) today reported financial results for the three months ended June 30, 2025, as well as key recent clinical and corporate developments. "Commercial and regulatory momentum for Multikine is accelerating due to three driving factors—our partnership negotiations in Saudi Arabia, the increasing interest in CEL-SCI from investors in the Middle East, and continued recognition in the global scientific and regulatory community that PD-L1 is a valuable

    8/14/25 10:45:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

    Memorandum of Understanding (MOU) signed with a leading Saudi Arabian pharma company which submitted the Breakthrough Medicine Designation to the Saudi Food and Drug Authority (SFDA) Increasing interest in CEL-SCI from Saudi investment funds as Multikine advances through regulatory and drug distribution channels CEL-SCI Corporation (NYSE:CVM) today announced that a Breakthrough Medicine Designation application has been filed with the Saudi Food and Drug Authority (SFDA) for Multikine* (Leukocyte Interleukin, Injection) in the Kingdom of Saudi Arabia by one of the Kingdom's premier pharmaceutical and healthcare companies. CEL-SCI has signed a Memorandum of Understanding (MOU) with thi

    8/13/25 9:15:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

    CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $5.7 million. The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate purposes, and working capital. ThinkEquity acted as the sole placement agent for the offer

    7/14/25 4:05:00 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    SEC Filings

    View All

    SEC Form 10-Q filed by Cel-Sci Corporation

    10-Q - CEL SCI CORP (0000725363) (Filer)

    8/14/25 9:31:38 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Cel-Sci Corporation

    EFFECT - CEL SCI CORP (0000725363) (Filer)

    8/13/25 12:15:19 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form S-3/A filed by Cel-Sci Corporation

    S-3/A - CEL SCI CORP (0000725363) (Filer)

    8/5/25 5:22:00 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care